European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 592-597 , December 2008

The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer

  • A. Montagnani

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • Corresponding Author InformationCorresponding author. Fax: +39 0577 233347.
    • ,
  • S. Gonnelli

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • A. Cadirni

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • C. Caffarelli

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • K. Del Santo

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • C. Pieropan

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • M.S. Campagna

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • M. Montomoli

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy
    • ,
  • R. Petrioli

      Affiliations

    • Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Italy
    • ,
  • R. Nuti

      Affiliations

    • Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy

Received 9 February 2007 ,Revised 29 April 2007 ,Accepted 6 May 2007.

References 

  1. National Center for Chronic Disease Prevention and Health Promotion. http//www.cdc.gov/nccdphp/bb_heartdisease/index.htm2004.
  2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357–3365
  3. Tamoxifene for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451–1467
  4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Brest Cancer Trialists' Collaborative Group. Lancet. 2005;365:1687–1717
  5. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–2442
  6. The ATAC Trialist's Group . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–2139
  7. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Deloizer T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  8. The Breast International Group (BIG) . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  9. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629
  10. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast. 2006;15:301–312
  11. Brown BW, Brauner C, Minotte MC. Non-cancer deaths in white adult cancer patients. J Natl Cancer Inst. 1993;85:979–987
  12. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47–63
  13. Rosano GM, Kaski JC, Arie S, Pereira WI, Horta P, Collins P, et al. Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J. 1996;17:1175–1180
  14. Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Steffanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  16. Bertelli G, Pronzato P, Amoroso D, Cuscimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988;12:307–310
  17. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. Br Med J. 1992;305:225–226
  18. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–1539
  19. Morales M, Santana N, Soria A, Mosquera A, Orvodas J, Novoa J, et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat. 1996;40:265–270
  20. Hozumi Y, Saito T, Inoue K, Saiozawa M, Omoto Y, Tabey T, et al. Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients—a preliminary study. Eur J Cancer. 2004;(Suppl 2):143
  21. Kataja V, Hietanen P, Joensuu H, Ala-Luhtala T, Asola R, Kokko R, et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer—a randomised study. Breast Cancer Res Treat. 2002;76(Suppl 1):S156
  22. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat. 2005;93:61–65
  23. Lønning E, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–5137
  24. Engan T, Krane J, Johannessen DC, Lonning PE, Kvinnsland S. Plasma change in breast cancer patients during endocrine therapy-lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat. 1995;36:287–297
  25. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, “Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients”. Ann Oncol. 2004;15:211–217
  26. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361, 662 men. Lancet. 1986;2:933–936
  27. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15
  28. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388
  29. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B
  30. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943–949
  31. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol. 2006;97(suppl 1):3A–11A

PII: S0953-6205(08)00071-X

doi: 10.1016/j.ejim.2007.05.016

European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 592-597 , December 2008

Article Tools

* Image Usage & Resolution